The safety of vedolizumab for ulcerative colitis and Crohn's disease

OBJECTIVE: Vedolizumab is a gut-selective antibody to α(4)β(7) integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. DESIGN: Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Colombel, Jean-Frédéric, Sands, Bruce E, Rutgeerts, Paul, Sandborn, William, Danese, Silvio, D'Haens, Geert, Panaccione, Remo, Loftus, Edward V, Sankoh, Serap, Fox, Irving, Parikh, Asit, Milch, Catherine, Abhyankar, Brihad, Feagan, Brian G
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Inflammatory Bowel Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531223/
https://ncbi.nlm.nih.gov/pubmed/26893500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2015-311079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados